{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:44:39Z","timestamp":1780321479628,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["L248022"],"award-info":[{"award-number":["L248022"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-128"],"award-info":[{"award-number":["2022-PUMCH-B-128"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-061"],"award-info":[{"award-number":["2021-I2M-1-061"]}]},{"name":"CSCO-hengrui Cancer Research Fund","award":["Y-HR2019-0239, Y-HR2020QN-0414"],"award-info":[{"award-number":["Y-HR2019-0239, Y-HR2020QN-0414"]}]},{"name":"CSCO-MSD Cancer Research Fund","award":["Y-MSDZD2021-0213"],"award-info":[{"award-number":["Y-MSDZD2021-0213"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15586-2","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:55:10Z","timestamp":1768902910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ziyue","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taifeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunda","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"Suppl","key":"15586_CR1","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31(Suppl):S228\u201354.","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"15586_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.medj.2021.03.002","volume":"2","author":"S Gallage","year":"2021","unstructured":"Gallage S, Garc\u00eda-Beccaria M, Szydlowska M, et al. The therapeutic landscape of hepatocellular carcinoma. Med. 2021;2(5):505\u201352.","journal-title":"Med"},{"key":"15586_CR3","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365.","journal-title":"Hepatology"},{"issue":"2","key":"15586_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"key":"15586_CR5","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMe0807581","volume":"359","author":"M Sherman","year":"2008","unstructured":"Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med. 2008;359:2045\u20137.","journal-title":"N Engl J Med"},{"issue":"9","key":"15586_CR6","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-17-2899","volume":"24","author":"Z Wang","year":"2018","unstructured":"Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24(9):2074\u201381.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"15586_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.21037\/hbsn-21-288","volume":"12","author":"WT Yan","year":"2023","unstructured":"Yan WT, Li C, Yao LQ, et al. Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study. Hepatobil Surg Nutr. 2023;12(2):155.","journal-title":"Hepatobil Surg Nutr"},{"issue":"3","key":"15586_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","volume":"154","author":"XF Xu","year":"2019","unstructured":"Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;154(3):209\u201317.","journal-title":"JAMA Surg"},{"key":"15586_CR9","first-page":"61","volume":"38","author":"W Wei","year":"2018","unstructured":"Wei W, Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond). 2018;38:61.","journal-title":"Cancer Commun (Lond)"},{"issue":"20","key":"15586_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"key":"15586_CR11","doi-asserted-by":"publisher","first-page":"102622","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"ZC Jin","year":"2024","unstructured":"Jin ZC, Chen JJ, Zhu XL, et al. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine. 2024;72:102622.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"15586_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns S, Corbett V, Yarchoan M, et al. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: A review. JAMA Oncol. 2024;10(3):395\u2013404.","journal-title":"JAMA Oncol"},{"issue":"10415","key":"15586_CR13","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835\u201347.","journal-title":"Lancet"},{"issue":"12","key":"15586_CR14","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"12","key":"15586_CR15","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial. JAMA Oncol. 2023;9(12):1651\u20139.","journal-title":"JAMA Oncol"},{"issue":"10408","key":"15586_CR16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, et al. Camrelizumab plus Rivoceranib versus Sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346.","journal-title":"Lancet"},{"issue":"7","key":"15586_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00252-7.","journal-title":"Lancet Oncol"},{"issue":"25","key":"15586_CR18","first-page":"00059","volume":"S2468\u20131253","author":"Y Shi","year":"2025","unstructured":"Shi Y, Han G, Zhou J, et al. Toripalimab plus bevacizumab versus Sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2025;S2468\u20131253(25):00059\u20137.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"15586_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant Sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344\u201354.","journal-title":"Lancet Oncol"},{"issue":"04","key":"15586_CR20","first-page":"437","volume":"22","author":"Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma","year":"2023","unstructured":"Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma. edition) [J]. Chin J Dig Surg 2023. 2023;22(04):437\u201348.","journal-title":"Chin J Dig Surg 2023"},{"issue":"6","key":"15586_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.hpb.2019.12.013","volume":"22","author":"W Chen","year":"2020","unstructured":"Chen W, Ma T, Zhang J, et al. A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. HPB (Oxford). 2020;22(6):795\u2013808.","journal-title":"HPB (Oxford)"},{"issue":"2","key":"15586_CR22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12072-022-10478-6","volume":"17","author":"W Chen","year":"2023","unstructured":"Chen W, Hu S, Liu Z, et al. Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. Hepatol Int. 2023;17(2):406\u201316.","journal-title":"Hepatol Int"},{"key":"15586_CR23","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/JHC.S424616","volume":"10","author":"J Ouyang","year":"2023","unstructured":"Ouyang J, Wang Z, Yuan K, et al. Adjuvant lenvatinib plus PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy: a retrospective landmark analysis. J Hepatocell Carcinoma. 2023;10:1465\u201377.","journal-title":"J Hepatocell Carcinoma"},{"issue":"4","key":"15586_CR24","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i4.101371","volume":"17","author":"JL Lu","year":"2025","unstructured":"Lu JL, Cheng Y, Xu ZL, et al. Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma. World J Gastrointest Oncol. 2025;17(4):101371.","journal-title":"World J Gastrointest Oncol"},{"key":"15586_CR25","doi-asserted-by":"publisher","first-page":"1202039","DOI":"10.3389\/fimmu.2023.1202039","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, Wang WQ, Zhu RH, et al. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors. Front Immunol. 2023;14:1202039.","journal-title":"Front Immunol"},{"issue":"10474","key":"15586_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405(10474):203\u201315.","journal-title":"Lancet"},{"key":"15586_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"15586_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ctrv.2018.08.006","volume":"74","author":"X Chang","year":"2019","unstructured":"Chang X, Lu X, Guo J, et al. Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treat Rev. 2019;74:49\u201360.","journal-title":"Cancer Treat Rev"},{"key":"15586_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/SLA.0000000000002727","volume":"268","author":"G Huang","year":"2018","unstructured":"Huang G, Li PP, Lau WY, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg. 2018;268:943\u201354.","journal-title":"Ann Surg"},{"key":"15586_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.23.00757","volume":"42","author":"DQ Huang","year":"2024","unstructured":"Huang DQ, Hoang JK, Kamal R, et al. Antiviral therapy utilization and 10-year outcomes in resected hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma. J Clin Oncol. 2024;42:790\u20139.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15586-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:57:41Z","timestamp":1770983861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15586-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15586"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15586-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of PUMCH (No. JS-1391) and Beijing Youan Hospital, Capital Medical University (No. LL-2020-125-K). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}